Macrolide-resistant Mycoplasma pneumoniae: characteristics of isolates and clinical aspects of community-acquired pneumonia. 2010

Miyuki Morozumi, and Takashi Takahashi, and Kimiko Ubukata
Laboratory of Molecular Epidemiology for Infectious Agents, Graduate School of Infection Control Sciences, Kitasato Institute for Life Sciences, Kitasato University, 5-9-1 Shirokane, Minatoku, Tokyo, 108-8641, Japan. miyuki@lisci.kitasato-u.ac.jp

Mycoplasma pneumoniae is one of the main pathogens causing community-acquired respiratory tract infections in children and adults. Macrolide (ML) antibiotics are recognized generally as first-choice agents for M. pneumoniae infections, and these antibiotics were thought to have excellent effectiveness against M. pneumoniae for many years. In 2000, however, M. pneumoniae showing resistance to macrolides was isolated from clinical samples obtained from Japanese pediatric patients with community-acquired pneumonia (CAP). Since then, prevalence of ML-resistant M. pneumoniae isolates in pediatric patients has increased rapidly. In 2007, ML-resistant M. pneumoniae isolates were obtained from Japanese adults with CAP; numbers of such isolates also have gradually increased in Japan. Recently, similar antimicrobial resistance in M. pneumoniae has begun to emerge worldwide. In this review, we focus on changes of ML-resistant M. pneumoniae from year to year and consider resistance mechanisms as well as clinical features of patients with resistant M. pneumoniae infection.

UI MeSH Term Description Entries
D009177 Mycoplasma pneumoniae Short filamentous organism of the genus Mycoplasma, which binds firmly to the cells of the respiratory epithelium. It is one of the etiologic agents of non-viral primary atypical pneumonia in man. Eaton Agent
D011019 Pneumonia, Mycoplasma Interstitial pneumonia caused by extensive infection of the lungs (LUNG) and BRONCHI, particularly the lower lobes of the lungs, by MYCOPLASMA PNEUMONIAE in humans. In SHEEP, it is caused by MYCOPLASMA OVIPNEUMONIAE. In CATTLE, it may be caused by MYCOPLASMA DISPAR. Mycoplasma Pneumonia,Pneumonia, Primary Atypical,Mycoplasma dispar Infection,Mycoplasma ovipneumoniae Infection,Mycoplasma pneumoniae Infection,Atypical Pneumonia, Primary,Atypical Pneumonias, Primary,Mycoplasma Pneumonias,Mycoplasma dispar Infections,Mycoplasma ovipneumoniae Infections,Mycoplasma pneumoniae Infections,Pneumonias, Mycoplasma,Pneumonias, Primary Atypical,Primary Atypical Pneumonia,Primary Atypical Pneumonias
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D017714 Community-Acquired Infections Any infection acquired in the community, that is, contrasted with those acquired in a health care facility (CROSS INFECTION). An infection would be classified as community-acquired if the patient had not recently been in a health care facility or been in contact with someone who had been recently in a health care facility. Community Acquired Infection,Community-Acquired Infection,Infections, Community-Acquired,Acquired Infection, Community,Acquired Infections, Community,Community Acquired Infections,Infection, Community Acquired,Infection, Community-Acquired,Infections, Community Acquired
D018942 Macrolides A group of often glycosylated macrocyclic compounds formed by chain extension of multiple PROPIONATES cyclized into a large (typically 12, 14, or 16)-membered lactone. Macrolides belong to the POLYKETIDES class of natural products, and many members exhibit ANTIBIOTIC properties. Macrolide
D024881 Drug Resistance, Bacterial The ability of bacteria to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance, Bacterial,Antibacterial Drug Resistance

Related Publications

Miyuki Morozumi, and Takashi Takahashi, and Kimiko Ubukata
November 2020, Indian journal of pediatrics,
Miyuki Morozumi, and Takashi Takahashi, and Kimiko Ubukata
October 2010, International journal of antimicrobial agents,
Miyuki Morozumi, and Takashi Takahashi, and Kimiko Ubukata
July 2020, Emerging infectious diseases,
Miyuki Morozumi, and Takashi Takahashi, and Kimiko Ubukata
May 2012, BMC infectious diseases,
Miyuki Morozumi, and Takashi Takahashi, and Kimiko Ubukata
November 2009, Respirology (Carlton, Vic.),
Miyuki Morozumi, and Takashi Takahashi, and Kimiko Ubukata
February 2020, Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit,
Miyuki Morozumi, and Takashi Takahashi, and Kimiko Ubukata
March 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Miyuki Morozumi, and Takashi Takahashi, and Kimiko Ubukata
January 2014, Swiss medical weekly,
Miyuki Morozumi, and Takashi Takahashi, and Kimiko Ubukata
February 2011, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy,
Miyuki Morozumi, and Takashi Takahashi, and Kimiko Ubukata
January 2019, BioMed research international,
Copied contents to your clipboard!